Core Insights - Silexion Therapeutics Corp. is a clinical-stage biotechnology company focused on RNA interference therapies for KRAS-driven cancers [1][3] - The company will present at the 27th Annual H.C. Wainwright Global Investment Conference on September 10, 2025 [1][2] - Silexion's lead product candidate targets locally advanced pancreatic cancer and has shown positive trends in a Phase 2a clinical trial compared to chemotherapy alone [3] Company Presentation Details - The presentation is scheduled for September 10, 2025, at 2:00 PM ET [2] - An updated company presentation is available on Silexion's investor website [2] - Management will be available for one-on-one investor meetings during the conference [2] Company Background - Silexion Therapeutics is dedicated to developing innovative treatments for solid tumor cancers with mutated KRAS oncogenes, which are prevalent in human cancers [3] - The company aims to advance therapeutic options in oncology, particularly for patients with unsatisfactorily treated cancers [3]
Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference